Search Result

Results for "

splice

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (2) ADC Cytotoxin (1) Akt (1) Androgen Receptor (3) Apoptosis (6) Autophagy (3) c-Met/HGFR (1) Carbonic Anhydrase (1) CCR (2) CDK (3) DNA/RNA Synthesis (22) E1/E2/E3 Enzyme (1) Glutaminase (2) Histone Methyltransferase (1) HIV (1) Huntingtin (1) iGluR (2) Integrin (2) IRE1 (3) Isotope-Labeled Compounds (2) MMP (1) Molecular Glues (1) NF-κB (1) Nucleoside Antimetabolite/Analog (1) P-glycoprotein (1) Phosphatase (1) Phosphodiesterase (PDE) (1) Potassium Channel (2) PROTACs (2) Proteasome (1) Raf (1) SF3B1 (3) SRPK (1) VEGFR (1)
By Research Areas:	Cancer (35) Cardiovascular Disease (1) Endocrinology (2) Infection (1) Inflammation/Immunology (9) Metabolic Disease (2) Neurological Disease (14)

By Targets:

Acyltransferase (2)

ADC Cytotoxin (1)

Akt (1)

Androgen Receptor (3)

Apoptosis (6)

Autophagy (3)

c-Met/HGFR (1)

Carbonic Anhydrase (1)

CCR (2)

CDK (3)

DNA/RNA Synthesis (22)

E1/E2/E3 Enzyme (1)

Glutaminase (2)

Histone Methyltransferase (1)

HIV (1)

Huntingtin (1)

iGluR (2)

Integrin (2)

IRE1 (3)

Isotope-Labeled Compounds (2)

MMP (1)

Molecular Glues (1)

NF-κB (1)

Nucleoside Antimetabolite/Analog (1)

P-glycoprotein (1)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

Potassium Channel (2)

PROTACs (2)

Proteasome (1)

Raf (1)

SF3B1 (3)

SRPK (1)

VEGFR (1)

By Research Areas:

Cancer (35)

Cardiovascular Disease (1)

Endocrinology (2)

Infection (1)

Inflammation/Immunology (9)

Metabolic Disease (2)

Neurological Disease (14)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16466

Spliceostatin A	SF3B1	Cancer
Spliceostatin A, the FR901464 (HY-16212) methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells .

HY-147149

BPN-15477	Others	Neurological Disease
BPN-15477 is a potent SMC (splicing modulator compound) that restores correct splicing of ELP1 (Elongator complex protein 1) exon 20. BPN-15477 corrects splicing of the ELP1 transcript, significantly increases the level of functional protein in vivo in all tissues, including brain. BPN-15477 can be used for frontotemporal dementia research .

HY-148384A

UHMCP1 dihydrochloride	Others	Cancer
UHMCP1 dihydrochloride is a potent UHM domain splicing inhibitor with a K_d value of 79 µM. UHMCP1 dihydrochloride prevents the SF3b155/U2AF ⁶⁵ interaction. UHMCP1 dihydrochloride impacts cell viability and RNA splicing .

HY-155812

Tyrosine kinase-IN-6

c-Met/HGFR Cancer

Tyrosine kinase-IN-6 is a potent and promising RON splice variants inhibitor with anti-cancer and o?antineoplastic effects .

Tyrosine kinase-IN-6	c-Met/HGFR	Cancer
Tyrosine kinase-IN-6 is a potent and promising *RON splice* variants** inhibitor with anti-cancer and o?antineoplastic effects .

HY-139104

Thailanstatin D	DNA/RNA Synthesis Apoptosis	Cancer
Thailanstatin D, an analogue of Thailanstatin A, is able to inhibit AR-V7 gene splicing by interfering the interaction between U2AF65 and SAP155 and preventing them from binding to polypyrimidine tract located between the branch point and the 3' splice site. Thailanstatin D exhibits a potent tumor inhibitory effect on human CRPC xenografts leading to cell apoptosis .

HY-135785

OSMI-3	Acyltransferase	Metabolic Disease
OSMI-3 (Compound 2b) is a potent, long-lasting, and cell-permeable O-linked N-acetylglucosamine transferase (OGT) inhibitor. Cells contain a large nuclear pool of partially spliced OGT transcript, and OSMI-3 increases detained intron splicing in cells .

HY-139103

Thailanstatin C

DNA/RNA Synthesis Cancer

Thailanstatin C is a pre-mRNA splicing inhibitor (IC₅₀= 6.84 μM) and antiproliferative agent from Burkholderia thailandensis MSMB43 .

Thailanstatin C	DNA/RNA Synthesis	Cancer
Thailanstatin C is a pre-mRNA splicing inhibitor (IC₅₀= 6.84 μM) and antiproliferative agent from Burkholderia thailandensis MSMB43 .

HY-148384

UHMCP1	Others	Cancer
UHMCP1 is a chemical probe of U2AF homology motifs (UHM) with a K_d of 79 μM. UHMCP1 prevents the SF3b155/U2AF65 interaction, impacts RNA splicing and cell viability. UHMCP1 has potential anticancer properties .

HY-18509

IRE1α kinase-IN-2	IRE1	Cancer
IRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC₅₀ of 0.82 μM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC₅₀=3.12 μM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines .

HY-16399

Pladienolide B	Apoptosis SF3B1	Cancer
Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis .

HY-150247

RNA splicing modulator 2

DNA/RNA Synthesis Others

RNA splicing modulator 2 (compound 256) is a RNA splicing modulator .

RNA splicing modulator 2	DNA/RNA Synthesis	Others
RNA splicing modulator 2 (compound 256) is a RNA splicing modulator .

HY-100236

Madrasin 4 Publications Verification DDD00107587	Others	Cancer
Madrasin (DDD00107587) is a splicing inhibitor that prevents formation of both splicing intermediates and products in vitro and interferes with one or more early steps in the pathway of spliceosome assembly. Madrasin also can inhibit pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA in cells .

HY-150246

RNA splicing modulator 1

DNA/RNA Synthesis Others

RNA splicing modulator 1 (compound 233) is a RNA splicing modulator, with an AC₅₀ value of <100 nM .
HY-150248

RNA splicing modulator 3

DNA/RNA Synthesis Others

RNA splicing modulator 3 (compound 236) is a RNA splicing modulator, with an AC₅₀ value of <100 nM .

RNA splicing modulator 1	DNA/RNA Synthesis	Others
RNA splicing modulator 1 (compound 233) is a RNA splicing modulator, with an AC₅₀ value of <100 nM .

RNA splicing modulator 3	DNA/RNA Synthesis	Others
RNA splicing modulator 3 (compound 236) is a RNA splicing modulator, with an AC₅₀ value of <100 nM .

HY-12248

Telaglenastat Maximum Cited Publications 57 Publications Verification CB-839	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .

HY-12248A

Telaglenastat hydrochloride CB-839 hydrochloride	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy and has antitumor activity .

HY-111520

NVS-SM2	DNA/RNA Synthesis	Neurological Disease
NVS-SM2 is a potent, orally active and brain-penetrant SMN2 splicing enhancer with an EC₅₀ of 2 nM for SMN. NVS-SM2 enhances U1-pre-mRNA association. NVS-SM2 promotes exon 7 inclusion and restores normal survival motor neuron (SMN) protein expression. NVS-SM2 can be used for spinal muscular atrophy (SMA) research .

HY-136951

cp028

DNA/RNA Synthesis Cancer

cp028 is a potent pre-mRNA splicing inhibitor. cp028 inhibits splicing in HeLa nuclear extract with an IC₅₀ value of 54 µM .

cp028	DNA/RNA Synthesis	Cancer
cp028 is a potent pre-mRNA splicing inhibitor. cp028 inhibits splicing in HeLa nuclear extract with an IC₅₀ value of 54 µM .

HY-144399

CD33 splicing modulator 1	Others	Neurological Disease
CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease .

HY-144399A

CD33 splicing modulator 1 hydrochloride	Others	Neurological Disease
CD33 splicing modulator 1 (Compound 1) hydrochloride is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 hydrochloride increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 hydrochloride has the potential for the research of neurodegenerative disease including Alzheimer's disease .

HY-19620

Branaplam 5+ Cited Publications LMI070; NVS-SM1	DNA/RNA Synthesis Potassium Channel	Cancer
Branaplam (LMI070; NVS-SM1) is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC₅₀ of 20 nM for SMN. Branaplam inhibits human-ether-a-go-go-related gene (hERG) with an IC₅₀ of 6.3 μM. Branaplam elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .

HY-19620A

Branaplam hydrochloride 5+ Cited Publications LMI070 hydrochloride; NVS-SM1 hydrochloride	DNA/RNA Synthesis Potassium Channel	Cancer
Branaplam (LMI070; NVS-SM1) hydrochloride is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC₅₀ of 20 nM for SMN. Branaplam hydrochloride inhibits human-ether-a-go-go-related gene (hERG) with an IC₅₀ of 6.3 μM. Branaplam hydrochloride elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .

HY-P3522

REDV	Integrin	Cancer
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion .

HY-101792A

RG7800 tetrahydrochloride 5 Publications Verification RO6885247 tetrahydrochloride	DNA/RNA Synthesis	Neurological Disease
RG7800 hydrochloride is an orally active SMN2 splicing modulator, with EC_1.5xs of 23 nM and 87 nM for SMN2 splicing and SMN protein; RG7800 hydrochloride has the potential to treat spinal muscular atrophy.

HY-148828

LSP-GR3	iGluR
LSP-GR3 is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.

HY-148828A

LSP-GR3 sodium	iGluR	Neurological Disease
LSP-GR3 sodium is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.

HY-156650

Votoplam

DNA/RNA Synthesis Neurological Disease

Votoplam is a gene splicing modulator, used to inhibit Huntington's disease .

Votoplam	DNA/RNA Synthesis	Neurological Disease
Votoplam is a gene splicing modulator, used to inhibit Huntington's disease .

HY-P3522A

REDV TFA	Integrin	Cancer
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .

HY-135784

OSMI-2	Acyltransferase	Metabolic Disease
OSMI-2 (Compound 1b) is a cell-permeable O-linked N-acetylglucosamine transferase (OGT) inhibitor. Cells contain a large nuclear pool of partially spliced OGT transcript, and OSMI-2 increases detained intron splicing in cells .

HY-141881

PROTAC-O4I2	PROTACs Apoptosis SF3B1	Cancer
PROTAC-O4I2 is a PROTAC targets splicing factor 3B1 (SF3B1). PROTAC-O4I2 induces FLAG-SF3B1 degradation with an IC₅₀ value of 0.244 μM in K562 cells. PROTAC-O4I2 also induces cellular apoptosis in K562 WT cells .

HY-N2360

Hinokiflavone 1 Publications Verification	E1/E2/E3 Enzyme Apoptosis	Cancer
Hinokiflavone is a novel modulator of pre-mRNA splicing activity in vitro and in cellulo. Hinokiflavone blocks splicing of pre-mRNA substrates by inhibiting spliceosome assembly, specifically preventing B complex formation. Hinokiflavone is a SUMO protease inhibitor, inhibiting sentrin-specific protease 1 (SENP1) activity .

HY-153421

PRMT5-IN-28	Histone Methyltransferase	Cancer
PRMT5-IN-28 (compound 36) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) enzyme. Protein arginine methylation is a common post-translational modification involved in gene transcription, mRNA splicing, DNA repair, protein cellular localization, cell fate determination and signal transduction, etc. Abnormal PRMT5 can promote cancer cell proliferation, resist apoptosis, enhance invasion and metastasis, and affect immune escape .

HY-101792

RG7800

5 Publications Verification

RO6885247
DNA/RNA Synthesis Others

RG7800 is a SMN2 splicing modifier. RG7800 has the potential for spinal muscular atrophy treatment.

RG7800 5 Publications Verification RO6885247	DNA/RNA Synthesis	Others
RG7800 is a SMN2 splicing modifier. RG7800 has the potential for spinal muscular atrophy treatment.

HY-113821

1-Naphthyl phosphate potassium salt	Phosphatase	Others
1-Naphthyl phosphate potassium salt is a non-specific phosphatase inhibitor. 1-Naphthyl phosphate potassium salt decreases the splice-correcting effect .

HY-157261

UNC2383

Others Others

UNC2383 is an oligonucleotide enhancing compound that can enhance effects of antisense oligonucleotides (ASOs), and splice switching oligonucleotides (SSOs) .
HY-112633

SMN-C3

DNA/RNA Synthesis Others

SMN-C3 is an orally active SMN2 splicing modulator and has the potential to treat spinal muscular atrophy (SMA).
HY-126076

VPC-80051 racemate

Others Others

VPC-80051 racemate is a racemate of VPC-80051. VPC-80051 is a prototype inhibitor of the hnRNP A1 splicing factor .

UNC2383	Others	Others
UNC2383 is an oligonucleotide enhancing compound that can enhance effects of antisense oligonucleotides (ASOs), and splice switching oligonucleotides (SSOs) .

SMN-C3	DNA/RNA Synthesis	Others
SMN-C3 is an orally active *SMN2* splicing modulator and has the potential to treat spinal muscular atrophy (SMA).

VPC-80051 racemate	Others	Others
VPC-80051 racemate is a racemate of VPC-80051. VPC-80051 is a prototype inhibitor of the hnRNP A1 splicing factor .

HY-153736

NSC 194308	Others	Cancer
NSC 194308, a U2AF2-RNA complexes enhancer, increases association of the U2AF1-U2AF2-SF1-splice site RNA complex by binding a site between the U2AF2 RNA recognition motifs (RRM1 and RRM2). NSC 194308 inhibits pre-mRNA splicing by stalling spliceosome assembly at the point where U2AF helps recruit U2 snRNP to the branchpoint. NSC 194308 enhances the binding of pre-mRNA to U2AF2, selectively triggering cell death in leukemia cell lines containing spliceosome mutations .

HY-112980

Nusinersen	DNA/RNA Synthesis	Inflammation/Immunology
Nusinersen is an antisense oligonucleotide agent that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein .

HY-112980A

Nusinersen sodium	DNA/RNA Synthesis	Inflammation/Immunology
Nusinersen sodium is an antisense oligonucleotide agent that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein .

HY-124648

SMN-C2	DNA/RNA Synthesis	Inflammation/Immunology
SMN-C2, an analog of RG-7916, is a selective modulator of SMN2 gene splicing that acts by binding SMN2 pre-mRNA, thereby increasing far upstream element binding protein 1 (FUBP1) and KH-spliced RNA binding Protein affinity regulator protein (KHSRP) to the SMN2 pre-mRNA complex. SMN-C2 can be used in spinal muscular atrophy (SMA) research .

HY-156103

mHTT-IN-2	Huntingtin	Neurological Disease
mHTT-IN-2 (compound 27) is a potent inhibitor (EC₅₀=0.066 μM) of mutant huntingtin (mHTT). mHTT-IN-2 reduces canonical splicing of HTT RNA exons [49-50] and is a splicing regulator of the huntingtin (HTT) gene. mHTT-IN-2 exhibits inhibitory activity in vitro and in vivo in human HD stem cells and mouse BACHD models. mHTT-IN-2 may be used in the study of branaplam-related peripheral neuropathy .

HY-109101

Risdiplam 5+ Cited Publications RG7916; RO7034067	DNA/RNA Synthesis	Neurological Disease
Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed *SMN2* pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-134851

HIV-1 inhibitor-6	HIV	Infection
HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC₅₀s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC₅₀s ranging from 0.9 to 1.5 μM .

HY-145724

Drisapersen Kyndrisa; GSK2402968A; PRO051	Others	Others
Drisapersen, a antisense oligonucleotide, induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.

HY-104040

MKC8866 5+ Cited Publications Orin1001	IRE1	Cancer
MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC₅₀ of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC₅₀ of 0.52 μM and unstresses RPMI 8226 cells with an IC₅₀ of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .

HY-N2117

Isoginkgetin 10+ Cited Publications	MMP Akt NF-κB Proteasome Apoptosis Autophagy	Inflammation/Immunology Cancer
Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy .

HY-117960

Orismilast LEO-32731	Phosphodiesterase (PDE)	Inflammation/Immunology
Orismilast (LEO-32731) is an orally active and selective PDE4 inhibitor used for the research of inflammatory diseases. Orismilast demonstrates potent inhibition of PDE4B and PDE4D subtype splice variants .

HY-148772

PTC258	Others	Neurological Disease
PTC258 is a specific and orally active splicing modulator of Elongator complex protein 1 gene (ELP1). PTC258 increases the expression of ELP1 in vitro and in vivo. PTC258 is well tolerated in mouse model .

HY-109101S

Risdiplam-d4	DNA/RNA Synthesis	Neurological Disease
Risdiplam-d₄ is deuterium labeled Risdiplam. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels[1].

Cat. No.	Product Name	Target	Research Area

HY-P5960

PTBP1-RNA-binding inhibitor P6 TFA PTBP1 α3-helix derived peptide P6 TFA	Peptides	Others
PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .